Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393258 · ClinicalTrials.gov registry record · NA
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
A NA study of Astrocytoma and Glioma, Malignant, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05393258: Completed NA study of Astrocytoma and Glioma, Malignant, sponsored by Washington University School of Medicine.
NCT05393258 is a NA study of Astrocytoma and Glioma, Malignant that has completed, run by Washington University School of Medicine. The registered enrollment target is 13 participants, below the 49-participant average among 19 other Astrocytoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05393258, a NA study of Astrocytoma and Glioma, Malignant, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small doses on a specific timed interval, instead of delivering one large dose at one time. This technique may improve efficacy while reducing toxicity and improving patient quality of life.
Primary Outcome
Intolerable toxicities are defined as grade 3 or higher central nervous system (CNS) adverse events at least possibly related to radiation as graded by the Common Terminology Criteria for Adverse Events v5.0 with the exception of grade 3 fatigue, headache, nausea, and vomiting. Any serious adverse event leading to discontinuation of TMPRT that is at least possibly related will be considered an intolerable toxicity.
Conditions Studied
Interventions
- RADIATION temporally-modulated pulsed radiotherapy (TMPRT)
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2026-03-13 |
| Phase | NA |
What the finished NCT05393258 record still lists
NCT05393258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 49-participant average among 19 other Astrocytoma trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with Astrocytoma appearing as the primary indexed condition, and to 1 intervention - of which temporally-modulated pulsed radiotherapy (TMPRT) is the first listed.
NCT05393258 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05393258 about?
NCT05393258 is a clinical study titled "Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas". This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small doses on a specific ...
What is the current status of trial NCT05393258?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2022-06-28. Estimated completion is 2026-03-13.
What conditions does trial NCT05393258 study?
This clinical trial studies the following conditions: Astrocytoma, Glioma, Malignant, Oligodendroglioma, Adult.
What interventions are being tested in trial NCT05393258?
The interventions under investigation include: temporally-modulated pulsed radiotherapy (TMPRT) (RADIATION).
Who is sponsoring clinical trial NCT05393258?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05393258 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astrocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05393258's enrollment target sits among peer trials
13 18th of 19 higher than 2 of 19 other Astrocytoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Astrocytoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
RECRUITING · NA
-
FearLess in NeuroOncology
RECRUITING · NA
-
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
ACTIVE NOT RECRUITING · NA
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI